Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This study will treat patients with Metastatic Castration Resistant Prostate Cancer who have progressed following prior therapy. This is the first time this drug has ever been tested in patients, and so it will help to understand what type of side effects may occur with the drug treatment. It will also measure the the levels of drug in the body and preliminarily assess its anti-cancer activity as monotherapy.
Epistemonikos ID: 3766560140d80e2bee7ca6792a24c4d9c62bb095
First added on: May 07, 2024